WilmerHale Achieves Victory for Roche Diabetes Care Limited in UK

Download IconDownload Print IconPrint

WilmerHale Achieves Victory for Roche Diabetes Care Limited in UK

Client News

Related Solutions

Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
Clients trust us to protect their most important intellectual property matters.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A global team handling highly complex and sensitive matters in all aspects of litigation.
Focusing on international arbitration and dispute resolution, investigations, financial services enforcement, and IP litigation.
WilmerHale acted for Roche Diabetes Care Limited in its successful defense of a patent infringement action brought by Insulet Corporation before the High Court of England & Wales. Insulet had claimed that Roche’s Accu-Chek® Solo micropump infringed the claims of its patent and sought an injunction. The case came quickly to trial under the Court’s Shorter Trial Scheme and was heard in a three-day trial in May 2021. In a 127 page judgment, the Court held Insulet’s patent to be invalid and not infringed by Roche’s Accu-Chek® Solo micropump. The Court also denied Insulet permission to appeal the judgment and awarded costs to Roche. The team advising Roche was led by Partners Matthew Shade and Anthony Trenton with Associate Delicia Clarke and Senior Paralegal Kelly Burrowes. The full judgment can be found here, and the case is Insulet Corporation v Roche Diabetes Care Ltd., case number HP-2020-000026. Bob Gunther and Omar Khan lead the co-pending US litigation in the District of Delaware, Roche Diabetes Care, Inc. v. Insulet Corporation, 1:20-cv-00825-MN.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel